

STATE OF KANSAS
KANSAS PHARMACY BOARD

NOTICE OF PUBLIC HEARING ON PROPOSED ARTICLE

A public hearing will be conducted at 10:30 a.m., on the 11th day of March, 2010, at the Kansas University School of Pharmacy, 1251 Wescoe Hall Drive, 2056 Malott Hall, Room 2049, Lawrence, Kansas, to consider the amendments of 68-20-10a and 68-1-1b and the proposed 68-7-21 of the Kansas Pharmacy Board.

This 60-day notice of the public hearing shall constitute a public comment period for the purpose of receiving written public comments on the amendments of 68-20-10a and 68-1-1b and the proposed 68-7-21. All parties may submit written comments prior to the hearing to the Executive Secretary of the Kansas Pharmacy Board, Debra Billingsley, pharmacy@pharmacy.ks.gov or Landon State Office Building, 900 SW Jackson, Room 560, Topeka, Kansas 66612-1231. All interested parties will be given a reasonable opportunity to present their views orally on the amendment of the regulation during the hearing. In order to give all parties an opportunity to present their views, it may be necessary to request each participant to limit any oral presentation to five minutes.

Any individual with a disability may request accommodation in order to participate in the public hearing and may request the regulation and economic impact statement in an accessible format. Requests for accommodation to participate in the hearing should be made at least five working days in advance of the hearing by contacting the Kansas Pharmacy Board, Landon State Office Building, 900 SW Jackson, Room 560, Topeka, Kansas 66612-1231, (785) 296-4056. Handicapped parking is located along Sunnyside Avenue, which runs south of Malott Hall. If handicapped parking on Sunnyside Avenue is used, it is necessary to cross the street to enter into the first floor of Malott Hall. There also is handicapped parking located behind Malott Hall in

Lot #37. This lot is accessed by an alley that lies to the east of the Dole Human Development Center, which also is located to the east of Malott Hall. If Lot #37 is used, entry into Malott Hall would occur on the second floor of the building.

A summary of the amended and proposed regulations are as follows:

68-20-10a. Electronic prescription transmission of controlled substances. This regulation already identifies various provisions for electronic prescription transmission of controlled substances. The amended regulation is proposed to specify what constitutes a “long term care facility (LTCF)” for purposes of prescriptions by electronic transmission.

68-1-1b. Continuing education unit. This regulation provides the provisions for continuing educational units.

68-7-21. Institutional drug rooms. This regulation identifies the policies and procedures governing the storage and proper and consistent controls of drugs administered or dispensed in an Institutional Drug Room.

Copies of the regulation and the economic impact statement may be obtained from the Kansas Pharmacy Board, Landon State Office Building, 900 SW Jackson, Room 560, Topeka, Kansas 66612-1231, (785) 296-4056, or by accessing the Board’s website at <http://www.accesskansas.org/pharmacy/leg.html>.

Debra Billingsley
Executive Secretary

STATE OF KANSAS
KANSAS PHARMACY BOARD

ECONOMIC IMPACT STATEMENT

Pursuant to K.S.A. 77-420(b), the Kansas Pharmacy Board submits the following description of the economic impact of K.A.R. 68-1-1b.

1. This regulation provides the provisions for continuing educational units.
2. The proposed regulation is not mandated by federal laws.
3. No new costs will be borne by pharmacists, pharmacy technicians, or others.
4. The Board is not aware of any less costly or less intrusive methods to achieve the stated purpose and thus none were considered.
5. This is not a proposed environmental regulation.

68-1-1b. Continuing educational unit. (a) Ten clock-hours of continuing education approved by the board shall constitute one continuing educational unit (C.E.U.). "Continuing education" shall mean an organized and systematic education experience beyond basic preparation that is designed to achieve the following:

(1)(A) Increase knowledge, improve skills, or enhance the practice of pharmacy;
or

(B) improve protection of the public health and welfare; and

(2) ensure continued competence.

(b) Three C.E.U.s shall be required for renewal during each licensure period.

Continuing education hours may be prorated for licensure periods that are less than biennial at a rate of .125 C.E.U.s per month.

(c)(1) Each continuing education program ~~recognized~~ administered by a provider approved by the accreditation council for pharmacy education (ACPE) shall be approved by the board.

(2) Each continuing education program shall be a program of continuing education that has been approved by the board. Each provider not approved by the ACPE shall submit the continuing education program ~~shall be submitted~~ to the board at least 120 days in advance for consideration for approval. Except for continuing education programs ~~recognized by the ACPE and approved by the board~~ provided by an ACPE-approved provider, continuing education programs shall not include in-service programs, on-the-job training, orientation for a job, an education program open to the general public, a cardiopulmonary resuscitation (CPR) course, a basic cardiac life support (BCLS) course, emergency or disaster training or direct experience at a healthcare facility under a code

ATTORNEY GENERAL

DEPT. OF ADMINISTRATION

OCT 19 2009

APR 27 2009

APPROVED BY 

APPROVED

blue, testing out of a course, medical school courses, and continuing medical education (CME) category 1 programs.

~~(3) Continuing education credit received from any provider not recognized by the ACPE may be approved by the board after review and consideration of the following documentation submitted to the board by each licensee:~~

~~(A) A copy of the certification of attendance of completion for the program, which shall include the program title, type of course or program, name of provider, and the number of continuing education units completed; and~~

~~(B) a brief summary of the program stating the program's objectives and describing the relevance of the program to the practice of pharmacy.~~

(3) The criteria for continuing education specified in paragraphs (a)(1) and (2) shall be considered by the board when deciding whether to approve a continuing education program submitted by a provider not approved by the ACPE.

(d) Attendance at a scheduled board meeting shall be accepted by the board for C.E.U. credit according to this schedule:

(1) 0.1 C.E.U. for each two hours of attendance at a scheduled board meeting; and

(2) a maximum of 0.8 C.E.U. for a biennial licensing period.

(e) In each biennial licensing period, the total number of combined C.E.U. credits from attendance at programs of a provider not approved by the ACPE and from attendance at a scheduled board meeting shall not exceed 0.8 C.E.U., for purposes of meeting the continuing education requirement for license renewal.

(f) A licensee shall not be allowed to carry forward excess hours earned in one

ATTORNEY GENERAL

DEPT. OF ADMINISTRATION

OCT 19 2009

OCT 07 2009

APPROVED BY 

APPROVED

licensure period into the next licensure period. (Authorized by and implementing K.S.A. 65-1632; effective, E-76-31, Aug. 11, 1975; effective May 1, 1976; amended May 1, 1978; amended May 1, 1983; amended May 1, 1986; amended May 1, 1987; amended July 1, 1990; amended July 31, 1998; amended Oct. 20, 2006; amended P-
_____.)

ATTORNEY GENERAL

OCT 19 2009

APPROVED BY *W*

DEPT. OF ADMINISTRATION

OCT 07 2009

APPROVED